We analyzed causes of death, other than resistant disease or relapse, in 875 children with acute lymphoblastic leukemia (ALL) and 229 with acute myeloid leukemia (AML), treated on three different Dutch Childhood Oncology Group (DCOG) ALL and three AML protocols. Overall, 23 (2.6%) ALL and 44 (19.2%) AML patients died. Early death (ED, before remission was reached) occurred in nine ALL (1%) and thirty AML (13.1.%) patients, including three and ten deaths before treatment was initiated. Chemotherapy-related mortality in remission (CRM) occurred in nine ALL (1.1%) and eight AML (4.4%) patients. For ALL, both ED and CRM declined over time, although this was not statistically significant. For AML a decrease in ED was observed (from 26% to approximately 10%), but counterbalanced by an increase in CRM (from 3 to 8%), maybe related to the scheduling of intensification blocks in AML-92/94. Including transplant-related mortality, death in CR rates in AML increased from 3 to 15% in the last study. The main cause of ED was hemorrhage, often associated with hyperleucocytosis, and infection for CRM. We conclude that mortality dropped favorably in ALL, but not in AML. Especially for AML, effective but less toxic therapy and better supportive care guidelines need to be developed.
Introduction
Over the past decades, the survival rates for children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) have markedly improved. Current survival rates are approximately 80% for ALL and 50-70% for AML. [1] [2] [3] [4] [5] [6] This increase in survival is due to more effective antileukemic therapy, with reduction of the number of relapses and resistant disease, but also due to improvements in supportive care, such as antibiotics, antifungal treatment, blood banking, transplant procedures and pediatric intensive care. [6] [7] [8] [9] Improved surveillance, such as viral screening post-transplant may also play a role. However, further intensification of antileukemic treatment may increase treatment-related toxicity and mortality. Hence, a number of children with ALL or AML, who otherwise might have been cured, may die due to causes other than persistent leukemia or relapse. 10, 11 This prompted us to retrospectively evaluate the incidence and causes of death occurring on subsequent Dutch Childhood Oncology Group (DCOG) ALL and AML protocols, excluding death due to resistant disease or relapse. Our data are population based, as all children diagnosed with ALL or AML in The Netherlands are reported to the DCOG, and included in the studies presented here.
Part of the data on the clinical outcome of patients treated on these respective protocols have been reported elsewhere, but not in the context of early death and treatment-related mortality. [12] [13] [14] [15] Patients and methods
Patients and centers
All children diagnosed with ALL or AML in The Netherlands were eligible, including all patients diagnosed with leukemia who died before induction therapy was initiated. Patients with ALL were enrolled in the DCOG ALL-6 (n ¼ 190), ALL-7 (n ¼ 218) or ALL-8 (n ¼ 467) protocol (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) , and patients with AML were enrolled in the DCOG AML-82 (n ¼ 49), AML-87 (n ¼ 92) or AML-92/94 (n ¼ 88) protocol (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) . All children with leukemia were treated in one of the five pediatric oncology or two bone-marrow transplant centers in The Netherlands (all university hospitals). All allogeneic transplants were performed in two transplant centers. ALL patients were sometimes treated -under the authority of the pediatric oncology center -in collaboration with local hospitals, especially during maintenance therapy. The median number of ALL patients over this entire time period was 139 patients per center (range 59-192), and for AML was median 34 patients (range 11-48) per center.
Treatment-protocols
ALL protocols: A schematic overview of the ALL-protocols is given in Figure 1 . The DCOG ALL-6 (1984 ALL-6 ( -1988 protocol included children o15 years of age, with non-high risk ALL only White Blood Cell (WBC) count o50 Â 10 9 /l, no mediastinal mass, no mature B-cell phenotype, no central nervous system (CNS) involvement. 12 After a 6-week induction regimen, three courses of methotrexate were given, followed by maintenance therapy for a total therapy duration of 116 weeks. Maintenance consisted of oral 6-mercaptopurine and methotrexate (6-MP/ MTX), interrupted by 2-week courses of dexamethasone plus vincristine pulses. There was no randomization, and no prophylactic cranial radiation. CNS prophylaxis mainly consisted of prolonged intrathecal triple therapy.
The DCOG ALL-7 protocol was based on the ALL BerlinFrankfurt-Mü nster (BFM) 86 protocol, and enrolled children with newly diagnosed ALL between 1988 and 1991. 13 The patients were stratified into three risk groups, that is, standard risk (SRG), risk group (RG) and experimental group (EG), based on leukemia cell mass at diagnosis and response to initial treatment. The treatment protocol started with protocol I as induction regimen, followed by protocol M with high-dose methotrexate. Subsequently, a reinduction course (protocol II or E) was given, followed by maintenance therapy with 6-MP/MTX for a total therapy duration of 78 weeks. RG patients were randomized to receive an extra block of late intensification (protocol S). Sibling donor stem cell transplantation (SCT) was optional for patients in the EG-arm of the trial. Cranial irradiation was applied only in patients with initial CNS involvement (no prophylactic irradiation).
The DCOG ALL-8 protocol (1991 ALL-8 protocol ( -1996 was similar to the ALL-BFM-90 protocol, but no prophylactic cranial irradiation was given.
14 The patients were again stratified into three risk groups: standard (SRG), medium (MRG) and high risk (HRG). The treatment protocol consisted of induction with protocol IA for SRG and HRG patients, and protocol IA þ B for MRG patients, followed by consolidation and maintenance therapy, for a total therapy duration of 105 weeks. MRG patients were randomized to receive protocol M with either low-dose 6-MP orally or high-dose 6-MP IV. SRG patients were randomized to receive extra L-asparaginase (25000 IU/m 2 i.m. once weekly) or not. SCT was optional for HRG patients with a matching sibling donor.
AML protocols: A schematic overview of the AML-protocols is given in Figure 2 . Details and cumulative dosages of chemotherapy are summarized in Table 1 , as not all protocols have been published in detail elsewhere. The DCOG AML-82 protocol (1982) (1983) (1984) (1985) (1986) (1987) started with an induction course followed by an intensification block. 15 Subsequently, SCT was performed in children with a matched sibling donor; otherwise maintenance treatment was given for 52 weeks. Maintenance consisted of four different blocks of chemotherapy, each given four times, according to the VAPA-10 protocol this regimen was based upon. High-dose cytarabine i.v. was considered elective CNS treatment/prophylaxis.
The DCOG AML-87 trial enrolled children diagnosed between 1987 and 1992. This protocol was similar (regarding the intensive treatment phases) to the AML-BFM-87 protocol, 16 and started with an induction course, followed by a consolidation block. Subsequently two intensification courses were given. All patients received prophylactic intrathecal cytarabine injections. In addition, children with a WBC 470 Â 10 9 /l at diagnosis were treated with prophylactic cranial irradiation (according to age: below 1 year, no irradiation; 1-2 years, 12 Gray; 2-3 years, 15 Gray; 43 years, 18 Gray). No maintenance therapy was given. If a matching sibling donor was available, SCT was performed following consolidation chemotherapy.
The DCOG AML-92/94 protocol (Hählen et al, Med Pediatr Oncol 2001; 35: 251 [abstract]) enrolled patients diagnosed between 1992 and 1998, and was based on the AML-BFM 93 study. 4 The protocol started with a pilot phase in 1992, and was continued unchanged from 1994 onwards. It was designed with the aim to further improve prognosis by replacing daunorubicin in induction by idarubicin, and to reduce the number of early relapses by introducing an early intensification course. In addition, all children were to be transplanted following the 2nd intensification course, either by allograft in case an MSD was available, or by autograft. Consolidation was similar as in the DCOG AML-87 protocol, after which a second intensification course was given. CNS-prophylaxis consisted of intrathecal Figure 1 Schematic overview of the different treatment blocks of the DCOG ALL-6, ALL7 and ALL-8 treatment protocols. Protocol ALL-6 included nonhigh-risk patients only. In protocol ALL-8 HRG, patients received three times block HR 1-3, and therefore so nine blocks in total. RG1 and RG2 questioned wheather late intensification of treatment (with protocol S) improved outcome. SRG1 and SRG2 questioned whether the addition of L-ASP in SRG-2 improved outcome. MRG1 and MRG2 questioned whether high-dose 6-mercaptopurine i.v. improved outcome. Ind., induction; Prot, protocol; CNS, central nervous system-directed therapy; MSD, matched sibling donor; SRG, standard risk group; RG, risk group; EG, experimental group; MRG, medium risk group; HRG, high-risk group; L-ASP, L-asparaginase. 
Figure 2
Schematic overview of the different treatment blocks of the DCOG AML-82, -87 and -92/94 protocols. In study AML-87, only patients with a high risk of developing a central nervous system relapse received prophylactic irradiation (see text). In study AML-82 and -87, only patients with a matched sibling donor were transplanted, and in study 92/94 patients received either an allo-or autograft. 1 Patients with a WBC at diagnosis 4100 Â 10 9 /l, who achieve a partial response after the 1st induction course were treated with a second, similar, induction course. AML, acute myeloid leukemia; MSD, matched sibling donor.
Toxic deaths in childhood leukemia
AM Slats et al Table 1 Details of chemotherapy and cumulative dosages of the three DCOG AML studies Supportive care: Supportive care measures were described in all protocols, and consisted of cotrimoxazole prophylaxis to prevent Pneumocystis carinii pneumonia, transfusion guidelines, advise on treatment of febrile neutropenia with broadspectrum antibiotics/antifungals, and prevention of tumor lysis syndrome with hyperhydration, alkalinization and allopurinol. The use of selective gut decontamination was left to the discretion of the individual treatment center. For AML patients, prophylactic antifungal medication was advised from protocol AML-87 onwards. During maintenance therapy in ALL, aplasia was prevented by stepwise discontinuation of cotrimoxazole and/or chemotherapy in case of low WBCs. Before the start of an intensive block of chemotherapy, certain general and hematological criteria needed to be fulfilled, such as absence of mucositis or fever and a good general clinical condition, as well as recovery from aplasia.
Definitions and statistical analyses
Death before treatment (DBT) was defined as any death occurring before chemotherapy was initiated. Early death (ED) was defined as any death in induction, occurring before complete remission (CR) was achieved according to the protocol guidelines, and included DBT. Induction deaths were further subdivided by death in the first 2 weeks vs later deaths. Death in CR was defined as any death occurring in 1st complete remission due to causes other than relapsed leukemia. Only events which occurred within 1 month after stopping chemotherapy were included. Death in CR was further subdivided into transplant-procedure-related mortality (TRM) and chemotherapy-related mortality (CRM). To evaluate CRM, transplanted patients were censored from the date of transplant. Causes of death for TRM were not evaluated.
CR was defined as less than 5% blasts in the bone marrow, with regeneration of normal hematopoiesis, plus absence of leukemic cells in the spinal fluid or anywhere else. Patients who survived the induction chemotherapy, but who failed to achieve remission, were classified as nonresponders and excluded from further analysis. Relapse was defined as X5% blasts in the bone marrow, or pleiocytosis of X15/3 ml with blasts in the cerebrospinal fluid, or leukemic infiltration elsewhere.
Event-free survival (EFS) was defined as the time from diagnosis until the first adverse event, and included remission failure (event at day 0), relapse or death of any cause, or, in case no event occurred, until the day of last follow-up. Overall survival (OS) was defined as the time from diagnosis to death of any cause or last follow-up. Probabilities of survival (pEFS and pOS) were estimated using the Kaplan-Meier method.
The distribution of qualitative variables was compared with the w 2 test or with the two-tailed Fischer's exact test. Comparison of continuous variables was performed by Student's t-test. A Pvalue of o0.05 was considered statistically significant.
Results

Acute lymphoblastic leukemia
The three consecutive ALL protocols included a total of 875 newly diagnosed children with ALL, including 14 children with Down's syndrome (DS). Patient characteristics are shown in Table 2 , and survival estimates given in Table 3 .
ED occurred in nine children (1.0% of ALL patients), and consisted of three patients (1.6%) included in ALL-6; two (0.9%) in ALL-7; and four (0.9%) in ALL-8. When DBT was excluded these frequencies were 1.1, 0.9 and 0.4%, respectively (differences not statistically significant). ED occurred significantly more frequently in boys (P ¼ 0.006), in T-cell ALL (50% of patients with ED had T-cell ALL vs 10.6% in patients without ED, Po0.001), and in patients with high diagnostic white blood cell counts (WBC, defined as 4100 Â 10 9 /l; 44.4% in patients with ED vs 8.0% in the non-ED group, Po0.001). Immunophenotype and WBC are inter-related, as patients with T-ALL have significantly higher WBCs at diagnosis than patients with B-cell precursor ALL (median 67.3 vs 8.0 Â 10 9 /l, Po0.001). There was no significant difference in age between patients with and without ED. DS was significantly more frequent in patients with ED than in patients without ED (14.3 vs 1.4%, Po0.001).
Of the nine ED patients, three died before treatment was started (DBT), deaths being all due to intracerebral hemorrhage. Two of these children had a WBC of 4100 Â 10 9 /l at diagnosis. Of the other six children with ED, three died in the first 2 weeks of induction (intracranial hemorrhage in two, and tumor-lysis in one patient). Two of these children presented with a WBC 4100 Â 10 9 /l. The other 3 children died in the 2nd part of induction (infection in one patient, accidental intrathecal administration of vincristine in another one, and a sudden cardiac arrest of unknown cause in a child with DS).
CR was achieved by 854 children, of whom 14 died (overall 1.6% death in CR rate). This varied from 1.6% in protocol ALL-6, to 2.8% in ALL-7, and 1.1% in ALL-8. SCT was performed in 28 children, of whom five died due to TRM, and nine children died due to CRM (1.1%). A decline in CRM was seen from 1.6% (n ¼ 3) for ALL-6, to 1.4% for ALL-7 (n ¼ 3) and 0.7% for ALL-8 (n ¼ 3), however, this was not statistically significant. There was no significant relationship between CRM and sex, age, WBC or immunophenotype. Of these 9 children, 78% (n ¼ 7) died due to an infection: two children in ALL-6 (both with clinically documented infection but negative blood cultures), three in ALL-7 (one patient with Streptococcus viridans, one with Pseudomonas and one with Pneumocystis carinii), and 2 in ALL-8 (Aspergillus in one and another patient with clinically documented infection but negative blood cultures). One other patient died of an intracerebral hemorrhage related to thrombocytopenia in ALL-8. Of one patient in ALL-6, the cause of death could not be clarified. Children with CRM died median 29 weeks after initial diagnosis (range 9-106 weeks). The data are summarized in Table 3 .
Acute myeloid leukemia
A total of 229 children were enrolled in the DCOG AML protocols, including 14 children with DS. Patient characteristics are shown in Table 2 and survival estimates in Table 3 .
ED occurred in 30 children (13.1% of AML patients). There was a sharp and statistically significant decline in the ED rate from study AML-82 (n ¼ 13, 26.5%) to study AML-87 (n ¼ 8, 8.7%; P ¼ 0.005) and to study AML-92/94 (n ¼ 9, 10.2%; P ¼ 0013). When DBT was excluded, these frequencies were 20.4, 4.3 and 6.8%, respectively.
Patients with ED more frequently had high WBCs (4100 Â 10 9 /l), compared to patients without ED (46.7 vs 19.2%, P ¼ 0.004). Despite a higher frequency of FAB M4 and M5 in patients with ED, the difference was not statistically significant (66.7 vs 50%, P ¼ 0.09). Four out of the seven patients with FAB M3 died early, which occurred before ATRA was introduced in the treatment protocols for patients with acute promyelocytic leukemia (from protocol AML 92/94 onwards). There were no significant differences for sex (P ¼ 0.07) or for age (P ¼ 0.18), between patients with and without ED.
Of the 30 children with ED, 10 died (4.4% of all AML patients) before treatment was initiated (DBT). Their causes of death were hemorrhage in five children, cardiac decompensation in one, pulmonary leucostasis in one, and the cause of death could not be clarified further in three patients. Seven of the 10 DBT patients had a WBC 4100 Â 10.9/l.
Of the other 20 children with ED, 13 died in the first 2 weeks of induction chemotherapy. In 11 of these 13 patients, the major cause of death was bleeding (seven with a diagnostic WBC 4100 Â 10 9 /l). Of the other two patients one died due to cardiac failure, and in the other, the cause could not be clarified further. Of the seven patients who died in the 2nd part of induction, four died due to bleeding, one due to streptococcal septicemia, one due to ARDS secondary to a clinically documented fungal pneumonia and one due to cardiac failure. In total, ED occurred due to hemorrhage in 20 patients, respectively, 10 in AML-82 (20.4% of eligible patients), five in AML-87 (5.4%) and five in AML-92/94 (5.7%).
CR was achieved in 180 children, of whom 14 died (overall death in CR rate of 7.8%). This was 3.1% for protocol AML-82 and 2.6% for AML-87, but increased significantly to 15.3% in protocol AML-92/94 (P ¼ 0.007). SCT was performed in 82 children, of whom six died due to transplant-related causes (TRM). Eight children died due to CRM (4.4%), which declined from study AML-82 to study À87 from 3.1% (n ¼ 1) to 1.3% (n ¼ 1; P ¼ 0.52), but increased significantly in study AML-92/94 to 8.3% (n ¼ 6) (P ¼ 0.04). The one CRM patient in study AML-87 died 10.5 weeks after diagnosis during consolidation. In study AML-92/94, the six patients with CRM died median 21 weeks after diagnosis (range 15-23 weeks), either following the consolidation block (n ¼ 2) or the 2nd intensification course (n ¼ 4). There was no statistically significant relation between CRM and sex, age, FAB type or WBC. Two patients with CRM also had DS, vs 12 DS patients among those who remained alive in CR (25 vs 7%; P ¼ 0.06). Five patients died of infection (streptococcal sepsis in three patients and fungal infection in two), two patients died of intracerebral hemorrhage related to thrombocytopenia and one child died of multiple organ failure. The data are summarized in Table 3 .
ALL vs AML
Both the frequencies of ED as well as CRM were significantly higher in AML than in ALL (Pp0.001 and P ¼ 0.004, respectively). In the AML studies, 19.2% of enrolled patients had a diagnostic WBC 4100 Â 10 9 /l, vs 10.7% in the ALL-7 and ALL-8 studies (P ¼ 0.001). In AML-82, this percentage was 25.6, vs 18.5% in AML-87 and 14.8% in AML-92/94. Patient characteristics of patients included in the DCOG ALL-and AML protocols, including the characteristics of patients who died due to reasons other than progressive or relapsed leukemia ALL (acute lymphoblastic leukemia) studies AML studies ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; DBT, death before treatment was initiated; ED, early death, defined as any death occurring before the remission status was evaluated according to the protocol (therefore this also included the cases of DBT); CRM, chemotherapy-related mortality, which excluded transplant-procedure-related deaths; yrs, years; FAB, French-American-British morphology classification; WBC, white blood cell count; IPT, immunophenotype; BCP; B-cell precursor ALL; Uncl., unclassified.
Discussion
Within ALL, both ED and CRM favorably declined over time, although these changes were not statistically significant. This demonstrates the improvement in supportive care over time, given the fact that ALL-7 and ALL-8 protocols consisted of more intensive chemotherapy than the preceding protocol ALL-6, which included non-high-risk patients only. Patients who suffered from ED, which was mainly caused by hemorrhage, presented more frequently with hyperleucocytosis. This also explains the higher frequency of ED in T-cell ALL patients, who present with higher diagnostic WBCs. In addition, ED was found more frequently in DS patients. The ALL-BFM Study Group reported similar death rates for their studies ALL-BFM-86 and À90, 17 as did other collaborative groups. 10, 18, 19 The MRC identified high initial WBC and DS as risk factors for treatmentrelated mortality, whereas in other series, age was the main prognostic factor. 10, 19 The relatively low death rate due to infections in ALL patients might reflect the empiric use of broad spectrum antibiotics in case of neutropenic fever, as well as successful prevention of Pneumocystis carinii pneumonia. 9, 10 Some other cases of CRM may be readily preventable, such as accidental intrathecal vincristine administration. 20 With the current use of urate oxidase in patients at high-risk for tumorlysis syndrome, mortality due to electrolyte disturbances and renal failure should further decline. 21 Both the frequencies of ED as well as CRM were significantly higher in AML than in ALL. This may be related to the higher frequency of hyperleucocytosis in AML. 22 Moreover, AML blasts size is larger than in ALL, resulting in higher blood viscosity at similar WBCs. The higher rate of CRM in AML may be mainly due to the difference in treatment intensity, which is needed to cure these different types of leukemias.
Within AML, marked differences in the rates of ED and CRM over time were found. The ED-rate in study AML-82 was unacceptably high (26.5%), and dropped to approximately 10% in the subsequent studies AML-87 and À92/94, in line with published data from the AML-BFM group. 23 Two-third of the patients with ED died due to hemorrhage, mainly within the first 2 weeks after diagnosis. Hemorrhage may be secondary to infarction related to hyperleucocytosis and sludging. Hyperleucocytosis was present in almost 50% of patients with ED, vs 20% of AML cases in general. We observed a decline in the incidence of hyperleucocytosis over time, which may be explained by earlier referral and accessibility of laboratory facilities. Leukapheresis or exchange transfusion may lower the ED-rate, although prospective studies are lacking. The efficacy of leukapheresis for patients who already present with severe complications is limited. 24, 25 Porcu et al 26 suggest that cerebral infarction and/or hemorrhage are not due to sludging, but rather caused by direct endothelial damage, as a result from migration of leukemic cells into the perivascular spaces. Other measures Table 3 Overview of the rates of death other than progressive leukemia for the respective DCOG ALL and AML protocols a Protocol ALL-6 included nonhigh-risk patients only, whereas protocols ALL-7 and eight included all patients with ALL.
b
The ED-rate was further subdivided in DBT, death occurring in the first 2 weeks of treatment, and death occurring after 2 weeks of treatment, but before CR was achieved. c Includes 22 allo-grafts and 26 auto-grafts ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; DBT, death before treatment was initiated; ED, early death, defined as any death occurring before the remission status was evaluated according to the protocol (therefore this also included the cases of DBT); TRM, treatmentrelated mortality, which excluded transplant-procedure-related deaths; CR, complete remission, SCT, stem cell transplant; DCOG, Dutch Childhood Oncology Group; pEFS, probability of event-free survival; pOS probability of overall survival.
to prevent sludging include hyperhydration, a rapid -but careful (to prevent tumor lysis syndrome) -start with low-dose chemotherapy, and a restricted red blood cell transfusion policy, with the aim not to increase blood viscosity any further. For patients with acute promyelocytic leukemia, the early death rate due to coagulopathy has dropped significantly with the introduction of all-trans-retinoic acid. 27 The death in CR rate in AML increased to an unacceptably high level (15.3%) in study AML-92/94. This contributed to the slightly inferior overall survival when study AML-92/94 was compared with AML-87. In study AML-92/94, two-third of the patients in 1st CR were transplanted, and 10% died due to transplant-related complications, which is in agreement with transplant-related mortality rates reported by others. 5, 28 It remains questionable whether the increased risk of mortality does not outweigh the potential advantage of SCT in antileukemic control, but our studies were not designed to answer this question. 3, 29 The high number of children with CRM in study AML-92/94 (8%) was another major concern, and in contrast with the remarkably low rate of 1% in the AML-87 study. 23 Of interest, the number of children dying from CRM in the respective BFM-studies was rather stable. 23 The variation in our studies might just be related to the small number of patients treated with chemotherapy alone, but we sought other explanations regarding the differences in CRM rates. The cumulative cytarabine and etoposide drug dosages used in study AML-87 were slightly higher than in AML-92/94, but the latter contained different anthracyclines. In study AML-87, the two intensification courses were scheduled following the consolidation block (late intensification), whereas in AML-93, intensification was scheduled directly after induction (early intensification). In the AML-BFM 93 study, high-risk patients were randomized between early vs late intensification, and there was a tendency towards a higher fatal infection rate in the late intensification group. 30 Hence, CRM rates may be schedule dependent. The patients were treated in the same centers in all three AML-studies, and the limited number of patients per center precludes meaningful analysis of center effects. In the MRC AML-10 trial, a learning effect was observed, as mortality dropped from 17.8% in the first years of the trial to 9.6% in later years. 11 In our studies, a learning effect was not evaluable due to the small number of patients. Despite the fact that stopping rules were defined in the protocol, the criteria to stop the study were not formally met, although the number of deaths raised concern in the protocol committee. In conclusion, apart from the schedule of intensification blocks, we could not readily identify other causes to explain the differences in CRM rates.
Children with DS have an increased risk of toxicity due to intensive chemotherapy, which is confirmed in this study. 31, 32 Prognosis for children with DS and ALL is usually worse than for children with ALL without DS. This is caused by the lack of favorable biological characteristics and enhanced treatmentrelated toxicity. 31 AML in children with DS is a unique and chemo-sensitive disease, and best cure rates are probably achieved with moderate intensive AML chemotherapy without SCT, to avoid the increased risk of treatment-related mortality. 33, 34 We did not analyze events occurring later than 1 month after finishing chemotherapy. The death in CR rate may therefore be higher than we reported here, due to late effects such as cardiotoxicity, chronic GVHD and 2nd malignancies. [35] [36] [37] It has to be stressed that we included deaths occurring before treatment was initiated. In some studies, such patients are not eligible, resulting in under-reporting of disease-related mortality.
We conclude that the ED and CRM rates have dropped favorably over time for children with ALL, but this is not so for children with AML. The ED rate in AML has stabilized around 10% and is mainly related to hemorrhage and hyperleucocytosis, in the first 2 weeks after diagnosis. Prospective studies are needed to analyze the potential benefit of leukapheresis for hyperleucocytosis-induced complications. We observed an unacceptable rise in CRM in our AML-92/94 study, maybe related to the scheduling of the intensification courses. To improve the prognosis in childhood AML, further intensification of therapy may not be possible. Other strategies may involve the development of targeted therapy, which aims to specifically target the leukemic cells and hence reduce the toxicity on normal cells.
